Lincoln Pharma Q3 FY26 Revenue Rises 13.5% to ₹166.32 Cr

Lincoln Pharmaceuticals reports strong Q3 FY26 performance with revenue growth of 13.5% and net profit surge of 37.7% to ₹28.60 crores, driven by domestic and export expansion.

Lincoln Pharma Q3FY26 Net Profit Surges 37.70% YoY

Lincoln Pharmaceuticals reports consolidated net profit of ₹28.60 crore in Q3FY26, up 37.70% YoY. Revenue from operations grows 13.49% to ₹166.32 crore with strong performance across therapeutic segments.

Lincoln Pharmaceuticals Gets CRISIL A/Stable Rating

Lincoln Pharmaceuticals receives credit rating reaffirmation from CRISIL with long-term facilities at CRISIL A/Stable and short-term at CRISIL A1, reflecting strong financial profile.

Lincoln Pharma Reports 17% Net Profit Growth in Q1 Results

Lincoln Pharmaceuticals reported net profit of Rs 27.70 crore for the April-June quarter, marking a 17% increase from Rs 23.69 crore in the same period last year. Total income grew 7.3% to Rs 169.34 crore compared to Rs 157.69 crore in the previous year. EBITDA rose 17.92% to Rs 39.08 crore from Rs 33.14 crore year-on-year. The company targets Rs 1,000 crore revenue within three years through business expansion into high-value product lines and new markets, aiming for 15-18% annual growth driven by cardiac, diabetic, dermatology, and ENT segments. During the quarter, the company launched its bulk drug manufacturing plant with Rs 4 crore investment from internal funds and received approvals for 10 products. Company shares surged 8.47% to close at Rs 576.90 on BSE.